Mankind Pharma’s stock has rebounded 4.2% from its day’s low of ₹2,386.05, currently trading at ₹2,486 on the NSE. The stock opened at ₹2,453.95 and hit a high of ₹2,486.00, showing resilience after early session weakness.
Recent Developments
Mankind Pharma recently organized a healthcare camp at Mahakumbh 2025, offering medical assistance to pilgrims. The initiative highlights the company’s commitment to public health and social welfare.
Q3 Financial Performance
The company reported standalone net sales of ₹2,396.57 crore for December 2024, reflecting a 1.61% year-on-year growth. However, the stock saw a 6% decline after its Q3 results on January 24, 2025, due to lower net profit figures. Despite the recent earnings-driven correction, the stock’s intraday recovery signals positive investor sentiment and potential accumulation at lower levels.
Mankind Pharma’s stock opened at ₹2,453.95 and touched a high of ₹2,486.00 before dipping to its lowest point of ₹2,386.05 earlier in the session. However, it has since recovered by 4.2% to its current trading price of ₹2,486. This recovery indicates resilience in investor confidence despite recent selling pressure.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always consult a financial expert before making investment decisions.
